Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Non-Current Debt (2019 - 2026)

Alx Oncology Holdings' Non-Current Debt history spans 5 years, with the latest figure at $9.6 million for Q4 2023.

  • On a quarterly basis, Non-Current Debt rose 2.66% to $9.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $9.6 million, a 2.66% increase, with the full-year FY2023 number at $9.6 million, up 2.66% from a year prior.
  • Non-Current Debt hit $9.6 million in Q4 2023 for Alx Oncology Holdings, up from $9.6 million in the prior quarter.
  • Over the last five years, Non-Current Debt for ALXO hit a ceiling of $9.6 million in Q4 2023 and a floor of $1.4 million in Q4 2021.
  • Historically, Non-Current Debt has averaged $6.0 million across 5 years, with a median of $5.4 million in 2019.
  • Biggest five-year swings in Non-Current Debt: soared 570.64% in 2022 and later grew 2.66% in 2023.
  • Tracing ALXO's Non-Current Debt over 5 years: stood at $5.4 million in 2019, then tumbled by 41.17% to $3.2 million in 2020, then tumbled by 56.1% to $1.4 million in 2021, then soared by 570.64% to $9.4 million in 2022, then increased by 2.66% to $9.6 million in 2023.
  • Business Quant data shows Non-Current Debt for ALXO at $9.6 million in Q4 2023, $9.6 million in Q3 2023, and $9.5 million in Q2 2023.